TVRD · Tvardi Therapeutics
AI read · Neutral
The AI's read
This reflects one firm's view of Tvardi's shares, not a reported change in the company's business. The lower target points in a negative direction, but Oppenheimer kept its positive “Outperform” rating. Those mixed signals do not support a clear change in Tvardi's outlook.